27373893|t|Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data
27373893|a|To determine whether time to treatment following symptom onset differs between RA patients according to autoantibody status. A single-centre retrospective analysis of a UK early RA inception cohort was first undertaken to identify those components of the patient journey that differed by serological subtype. Data from a UK national audit of early inflammatory arthritis patients was accessed to replicate the key finding. A total of 173 RA patients were diagnosed over a 31- month period, of whom 80 (46%) were ACPA/RF double-seropositive (ACPA(+)/RF(+)), 53 (31%) ACPA(-)/RF(-), 17 (10%) ACPA(+)/RF(-) and 23 (13%) RF(+)/ACPA(-) Overall, ACPA(+)/RF(+) patients experienced significantly longer symptom duration before DMARD initiation. This was accounted for by delays in their presentation to primary care following symptom onset -a finding that was robustly confirmed in an independent dataset of 2192 UK early RA patients. In contrast, ACPA(-)/RF(-) patients were significantly more likely to experience delays in DMARD initiation after presenting to secondary care. Causes of treatment delays in early RA differ according to patients ' autoantibody status. More insidious symptom onset and/or distinct health-seeking behaviours among ACPA(+)/RF(+) patients may contribute to late presentations in primary care, whereas ACPA(-)/RF(-) patients experience delayed diagnosis and treatment in secondary care. These observations inform the research agenda, potentially influencing the design of service delivery for early arthritis patients.
27373893	14	23	treatment	T061	C0087111
27373893	24	29	delay	T079	C0205421
27373893	33	53	rheumatoid arthritis	T047	C0003873
27373893	54	60	differ	T080	C1705242
27373893	74	86	autoantibody	T116,T129	C0004358
27373893	87	93	status	T080	C0449438
27373893	95	105	validation	T062	C1519941
27373893	125	136	observation	T169	C1441672
27373893	137	142	using	T169	C1524063
27373893	143	151	national	T082	C0681788
27373893	152	157	audit	T169	C1704775
27373893	158	162	data	T078	C1511726
27373893	184	201	time to treatment	T079	C3494202
27373893	202	211	following	T079	C0332282
27373893	212	225	symptom onset	T079	C4086878
27373893	226	233	differs	T080	C1705242
27373893	242	244	RA	T047	C0003873
27373893	245	253	patients	T101	C0030705
27373893	267	279	autoantibody	T116,T129	C0004358
27373893	280	286	status	T080	C0449438
27373893	304	317	retrospective	T080	C1514923
27373893	318	326	analysis	T062	C0936012
27373893	332	334	UK	T083	C0041700
27373893	341	343	RA	T047	C0003873
27373893	344	360	inception cohort	UnknownType	C0150101
27373893	385	393	identify	T080	C0205396
27373893	418	425	patient	T101	C0030705
27373893	426	433	journey	T169	C1280477
27373893	439	447	differed	T080	C1705242
27373893	451	462	serological	T169	C0205473
27373893	463	470	subtype	T185	C0449560
27373893	472	476	Data	T078	C1511726
27373893	484	486	UK	T083	C0041700
27373893	487	495	national	T082	C0681788
27373893	496	501	audit	T169	C1704775
27373893	511	533	inflammatory arthritis	T047	C0003864
27373893	534	542	patients	T101	C0030705
27373893	547	555	accessed	T082	C0444454
27373893	559	568	replicate	T080	C1883725
27373893	577	584	finding	T033	C0243095
27373893	601	603	RA	T047	C0003873
27373893	604	612	patients	T101	C0030705
27373893	618	627	diagnosed	T060	C0430022
27373893	628	632	over	T079	C0347984
27373893	639	644	month	T079	C0439231
27373893	645	651	period	T079	C1948053
27373893	675	702	ACPA/RF double-seropositive	T034	C1254360
27373893	704	717	ACPA(+)/RF(+)	T034	C1254360
27373893	729	742	ACPA(-)/RF(-)	T034	C1254360
27373893	753	766	ACPA(+)/RF(-)	T034	C1254360
27373893	780	793	RF(+)/ACPA(-)	T034	C1254360
27373893	803	816	ACPA(+)/RF(+)	T034	C1254360
27373893	817	825	patients	T101	C0030705
27373893	852	858	longer	T080	C0205166
27373893	859	875	symptom duration	T079	C0436359
27373893	883	888	DMARD	T121	C0242708
27373893	889	899	initiation	T169	C1704686
27373893	927	933	delays	T079	C0205421
27373893	959	971	primary care	T058	C0033137
27373893	972	981	following	T079	C0332282
27373893	982	995	symptom onset	T079	C4086878
27373893	999	1006	finding	T033	C0243095
27373893	1025	1034	confirmed	T080	C0521093
27373893	1041	1052	independent	T169	C0332291
27373893	1053	1060	dataset	T170	C0150098
27373893	1069	1071	UK	T083	C0041700
27373893	1078	1080	RA	T047	C0003873
27373893	1081	1089	patients	T101	C0030705
27373893	1104	1126	ACPA(-)/RF(-) patients	T034	C1254360
27373893	1118	1126	patients	T101	C0030705
27373893	1172	1178	delays	T079	C0205421
27373893	1182	1187	DMARD	T121	C0242708
27373893	1188	1198	initiation	T169	C1704686
27373893	1219	1233	secondary care	T058	C3494402
27373893	1235	1241	Causes	T169	C0015127
27373893	1245	1254	treatment	T061	C0087111
27373893	1255	1261	delays	T079	C0205421
27373893	1271	1273	RA	T047	C0003873
27373893	1274	1280	differ	T080	C1705242
27373893	1294	1302	patients	T101	C0030705
27373893	1305	1317	autoantibody	T116,T129	C0004358
27373893	1318	1324	status	T080	C0449438
27373893	1331	1340	insidious	T080	C1288298
27373893	1341	1354	symptom onset	T079	C4086878
27373893	1371	1396	health-seeking behaviours	T055	C1321107
27373893	1403	1425	ACPA(+)/RF(+) patients	T034	C1254360
27373893	1417	1425	patients	T101	C0030705
27373893	1430	1440	contribute	T052	C1880177
27373893	1466	1478	primary care	T058	C0033137
27373893	1488	1510	ACPA(-)/RF(-) patients	T034	C1254360
27373893	1502	1510	patients	T101	C0030705
27373893	1522	1539	delayed diagnosis	T080	C2718036
27373893	1544	1553	treatment	T061	C0087111
27373893	1557	1571	secondary care	T058	C3494402
27373893	1579	1591	observations	T169	C1441672
27373893	1592	1598	inform	T058	C0700287
27373893	1603	1618	research agenda	T062	C0681798
27373893	1632	1643	influencing	T077	C4054723
27373893	1648	1654	design	T052	C1707689
27373893	1658	1674	service delivery	T058	C0011211
27373893	1679	1694	early arthritis	T047	C3899278
27373893	1695	1703	patients	T101	C0030705